Skip to main content
< Back to news
The researchers Luis Molinos and Carlota Dobaño, awarded in the last edition of the Campus Clínic Innova Awards. Image / Hospital Clínic
 03.11.2026

An ISGlobal project to develop the first malaria treatment based on a monoclonal antibody wins a Campus Clínic Innova Award

The latest edition of the Campus Clínic Innova Awards has recognised four projects from the Barcelona Institute for Global Health (ISGlobal), including ISG6.149, by Luis Molinos and Carlota Dobaño, the latter head of ISGlobal’s Malaria Immunology Group, based at the Barcelona Science Park (PCB-UB). The project focuses on the development of the first malaria treatment based on a monoclonal antibody isolated from a child, with activity against Plasmodium falciparum.

The Campus Clínic Innova Awards aim to support technology-based initiatives with potential for further development and transfer to the healthcare system. In this fifth edition, the ISG6.149 project was selected in the “Accelerem Idees” (Accelerating Ideas) category, aimed at innovation projects at more advanced stages of development, and received €30,000 in funding.

The research is based on a monoclonal antibody with activity against Plasmodium falciparum, the parasite responsible for the most severe form of malaria. The project seeks to advance its development and explore its potential as the basis for new strategies to prevent the disease. This funding and the associated support will provide an important boost to help the teams continue advancing the transfer of these scientific results into clinical practice and society.

The project led by Luis Molinos and Carlota Dobaño is one of four ISGlobal projects recognised under the “Idees cap al Mercat” (Ideas to Market) programme, which presented six awards this year. The other award-winning projects are EPI-FLARE, led by Juan Ramón González, which focuses on the use of epigenetics to improve the diagnosis of rare diseases and neurodevelopmental disorders; TARGET, led by Josep Maria Miró (IDIBAPS), with Jordi Vila leading the ISGlobal contribution, which explores the repurposing of elvitegravir as an antibiotic against resistant Gram-positive bacterial infections; and Obmetrics, led by Augusto Anguita-Ruiz, a virtual clinical platform for assessing cardiometabolic risk in children.

» Link to the news: Hospital Clínic website [+]